nach oben

Inflammopharmacology

Erschienen in:

02.03.2022 | Review

Osteopontin in autoimmune disorders: current knowledge and future perspective

verfasst von: Canhua Xu, Yaohong Wu, Ning Liu

Erschienen in: Inflammopharmacology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Osteopontin (OPN) is a multifunctional cytokine and adhesion molecule, as well as an unusual regulator for both innate and adaptive immune responses. Several immune cells can produce OPN, including dendritic cells (DCs), macrophages, and T lymphocytes. OPN expression is reported to be increased in a wide range of disorders, including autoimmunity, cancer, and allergy. The overexpression of OPN in several autoimmune disorders, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), Type 1 diabetes (T1D), inflammatory bowel disease (IBD), Sjögren’s, and myasthenia gravis, have been shown to be correlated with disease severity. Regarding the important regulatory roles of OPN in the immune system, this study aimed to review the role of this molecule in autoimmune disorders and to provide a complete view of the current knowledge in this field.

Afify MF, Mohamed GB, El-Maboud MMA, Abdel-Latif EA (2009) Plasma concentration of osteopontin (OPN) in children with systemic lupus erythematosus: relationship with disease activity. Open Autoimmun J 1:59–63

Agah E, Zardoui A, Saghazadeh A, Ahmadi M, Tafakhori A, Rezaei N (2018) Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: a systematic review and meta-analysis. PLoS ONE 13(1):e0190252PubMedPubMedCentral

Asadi G, Varmaziar FR, Karimi M, Rajabinejad M, Ranjbar S, Karaji AG et al (2021) Determination of the transcriptional level of long non-coding RNA NEAT-1, downstream target microRNAs, and genes targeted by microRNAs in diabetic neuropathy patients. Immunol Lett 232:20–26PubMed

Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S et al (2000) Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287(5454):860–864PubMed

Barchetta I, Alessandri C, Bertoccini L, Cimini F, Taverniti L, Di Franco M et al (2015) Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile. Eur J Endocrinol 174(2):187–192PubMed

Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8(3):212–226PubMedPubMedCentral

Bettini M, Vignali DA (2009) Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 21(6):612–618PubMedPubMedCentral

Boumans M, Houbiers J, Verschueren P, Ishikura H, Westhovens R, Brouwer E et al (2012) Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Ann Rheum Dis 71(2):180–185PubMed

Braitch M, Nunan R, Niepel G, Edwards LJ, Constantinescu CS (2008) Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Arch Neurol 65(5):633–635PubMed

Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT et al (2001) The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294(5547):1731–1735PubMed

Chiocchetti A, Indelicato M, Bensi T, Mesturini R, Giordano M, Sametti S et al (2004) High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation. Blood 103(4):1376–1382PubMed

Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sørensen ES (2005) Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 390(1):285–292PubMedPubMedCentral

Christensen B, Kazanecki CC, Petersen TE, Rittling SR, Denhardt DT, Sørensen ES (2007) Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem 282(27):19463–19472PubMed

Christensen B, Kläning E, Nielsen MS, Andersen MH, Sørensen ES (2012) C-terminal modification of osteopontin inhibits interaction with the αVβ3-integrin. J Biol Chem 287(6):3788–3797PubMed

Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Navarro JB et al (2005) Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 158(1–2):231–239PubMed

Comi C, Cappellano G, Chiocchetti A, Orilieri E, Buttini S, Ghezzi L et al (2012) The impact of osteopontin gene variations on multiple sclerosis development and progression. Clin Dev Immunol. https://doi.org/10.1155/2012/212893PubMedPubMedCentralCrossRef

Da Silva AP, Pollett A, Rittling SR, Denhardt DT, Sodek J, Zohar R (2006) Exacerbated tissue destruction in DSS-induced acute colitis of OPN-null mice is associated with downregulation of TNF-alpha expression and non-programmed cell death. J Cell Physiol 208(3):629–639. https://doi.org/10.1002/jcp.20701PubMedCrossRef

da Silva APB, Ellen RP, Sørensen ES, Goldberg HA, Zohar R, Sodek J (2009) Osteopontin attenuation of dextran sulfate sodium-induced colitis in mice. Lab Invest 89(10):1169–1181. https://doi.org/10.1038/labinvest.2009.80PubMedCrossRef

Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS (2001) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Investig 107(9):1055–1061PubMedPubMedCentral

Ebers GC (2008) Environmental factors and multiple sclerosis. Lancet Neurol 7(3):268–277PubMed

Ek-Rylander B, Andersson G (2010) Osteoclast migration on phosphorylated osteopontin is regulated by endogenous tartrate-resistant acid phosphatase. Exp Cell Res 316(3):443–451PubMed

Emily H-YC, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ (2001) BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 8(3):705–711

Essafi A, de Mattos SF, Hassen YA, Soeiro I, Mufti GJ, Thomas NSB et al (2005) Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 24(14):2317–2329PubMed

Fan K, Dai J, Wang H, Wei H, Cao Z, Hou S et al (2008) Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheumatism 58(7):2041–2052PubMed

Filippi M, Preziosa P, Langdon D, Lassmann H, Paul F, Rovira À et al (2020) Identifying progression in multiple sclerosis: new perspectives. Ann Neurol 88(3):438–452PubMed

Fisher L, Torchia D, Fohr B, Young M, Fedarko N (2001) Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 280(2):460–465PubMed

Franzen A, Heinegård D (1985) Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 232(3):715–724PubMedPubMedCentral

Frenzel DF, Borkner L, Scheurmann J, Singh K, Scharffetter-Kochanek K, Weiss JM (2015) Osteopontin deficiency affects imiquimod-induced psoriasis-like murine skin inflammation and lymphocyte distribution in skin, draining lymph nodes and spleen. Exp Dermatol 24(4):305–307. https://doi.org/10.1111/exd.12649PubMedCrossRef

Gazal S, Sacre K, Allanore Y, Teruel M, Goodall AH, Tohma S et al (2015) Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. Ann Rheum Dis 74(3):e19–e19PubMed

Gimba E, Tilli T (2013) Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett 331(1):11–17PubMed

Gordin D, Forsblom C, Panduru NM, Thomas MC, Bjerre M, Soro-Paavonen A et al (2014) Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes. Diabetes Care 37(9):2593–2600. https://doi.org/10.2337/dc14-0065PubMedCrossRef

Grassinger J, Haylock DN, Storan MJ, Haines GO, Williams B, Whitty GA et al (2009) Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with α9β1 and α4β1 integrins. Blood, J Am Soc Hematol 114(1):49–59

Harris VK, Sadiq SA (2014) Biomarkers of therapeutic response in multiple sclerosis: current status. Mol Diagn Ther 18(6):605–617PubMedPubMedCentral

Hejrati A, Hasani B, Esmaili M, Bashash D, Tavakolinia N, Zafari P (2021) Role of exosome in autoimmunity, with a particular emphasis on rheumatoid arthritis. Int J Rheum Dis 24(2):159–169PubMed

Howe HS, Leung BPL (2020) Anti-cytokine autoantibodies in systemic lupus erythematosus. Cells 9(1):72

Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L (2007) Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 8(1):74–83PubMed

Husain-Krautter S, Kramer JM, Li W, Guo B, Rothstein TL (2015) The osteopontin transgenic mouse is a new model for Sjögren’s syndrome. Clin Immunol 157(1):30–42. https://doi.org/10.1016/j.clim.2014.12.010PubMedPubMedCentralCrossRef

Icer MA, Gezmen-Karadag M (2018) The multiple functions and mechanisms of osteopontin. Clin Biochem 59:17–24PubMed

Iizuka J, Katagiri Y, Tada N, Murakami M, Ikeda T, Sato M et al (1998) Introduction of an osteopontin gene confers the increase in B1 cell population and the production of anti-DNA autoantibodies. Lab Invest 78(12):1523–1533PubMed

Inoue M, Shinohara ML (2011) Intracellular osteopontin (iOPN) and immunity. Immunol Res 49(1):160–172PubMedPubMedCentral

Inoue M, Moriwaki Y, Arikawa T, Chen Y-H, Oh YJ, Oliver T, Shinohara ML (2011) Cutting edge: critical role of intracellular osteopontin in antifungal innate immune responses. J Immunol 186(1):19–23PubMed

Iwadate H, Kobayashi H, Kanno T, Asano T, Saito R, Sato S et al (2014) Plasma osteopontin is correlated with bone resorption markers in rheumatoid arthritis patients. Int J Rheum Dis 17(1):50–56PubMed

Jansson M, Panoutsakopoulou V, Baker J, Klein L, Cantor H (2002) Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol 168(5):2096–2099PubMed

Ji H-I, Lee S-H, Song R, Yang H-I, Lee Y-A, Hong S-J et al (2014) Serum level of osteopontin as an inflammatory marker does not indicate disease activity or responsiveness to therapeutic treatments in patients with rheumatoid arthritis. Clin Rheumatol 33(3):397–402PubMed

Jono S, Peinado C, Giachelli CM (2000) Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 275(26):20197–20203PubMed

Junaid A, Moon MC, Harding GE, Zahradka P (2007) Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am J Physiol Cell Physiol 292(2):C919–C926PubMed

Kaleta B (2014) Role of osteopontin in systemic lupus erythematosus. Arch Immunol Ther Exp 62(6):475–482

Kalmarzi RN, Rajabinejad M, Lotfi R (2020) Immune semaphorins: crucial regulatory signals and novel therapeutic targets in asthma and allergic diseases. Eur J Pharmacol 881:173209PubMed

Kanayama M, Xu S, Danzaki K, Gibson JR, Inoue M, Gregory SG, Shinohara ML (2017) Skewing of the population balance of lymphoid and myeloid cells by secreted and intracellular osteopontin. Nat Immunol 18(9):973–984PubMedPubMedCentral

Kariuki SN, Moore JG, Kirou KA, Crow MK, Utset TO, Niewold TB (2009) Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun 10(5):487–494. https://doi.org/10.1038/gene.2009.15PubMedPubMedCentralCrossRef

Katagiri Y, Mori K, Hara T, Tanaka K, Murakami M, Uede T (1995) Functional analysis of the osteopontin molecule. Ann N Y Acad Sci 760(1):371–374PubMed

Kawamura K, Iyonaga K, Ichiyasu H, Nagano J, Suga M, Sasaki Y (2005) Differentiation, maturation, and survival of dendritic cells by osteopontin regulation. Clin Vaccine Immunol 12(1):206–212

Kawashiri S-Y, Endo Y, Nishino A, Okamoto M, Tsuji S, Takatani A et al (2021) Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan. BMC Musculoskelet Disord 22(1):506. https://doi.org/10.1186/s12891-021-04392-5PubMedPubMedCentralCrossRef

Kazanecki CC, Uzwiak DJ, Denhardt DT (2007) Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 102(4):912–924PubMed

Kiefer FW, Zeyda M, Gollinger K, Pfau B, Neuhofer A, Weichhart T et al (2010) Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 59(4):935–946. https://doi.org/10.2337/db09-0404PubMedPubMedCentralCrossRef

Kim J, Ahn M, Choi Y, Chun J, Jung K, Tanaka A et al (2022) Osteopontin is a biomarker for early autoimmune uveoretinitis. Neural Regen Res 17(7):1604PubMed

Kitagori K, Yoshifuji H (2017) Osteopontin in systemic lupus erythematosus. Nihon Rinsho Meneki Gakkai Kaishi 40(2):118–123. https://doi.org/10.2177/jsci.40.118PubMedCrossRef

Kitagori K, Yoshifuji H, Oku T, Sasaki C, Miyata H, Mori KP et al (2016) Cleaved form of osteopontin in urine as a clinical marker of lupus nephritis. PLoS ONE 11(12):e0167141. https://doi.org/10.1371/journal.pone.0167141PubMedPubMedCentralCrossRef

Kivisäkk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S et al (2013) Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler J 20(4):438–444. https://doi.org/10.1177/1352458513503052CrossRef

Kivisäkk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S et al (2014) Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler 20(4):438–444. https://doi.org/10.1177/1352458513503052PubMedCrossRef

Komine-Aizawa S, Masuda H, Mazaki T, Shiono M, Hayakawa S, Takayama T (2015) Plasma osteopontin predicts inflammatory bowel disease activities. Int Surg 100(1):38–43. https://doi.org/10.9738/intsurg-d-13-00160.1PubMedPubMedCentralCrossRef

Kon S, Nakayama Y, Matsumoto N, Ito K, Kanayama M, Kimura C et al (2014) A novel cryptic binding motif, LRSKSRSFQVSDEQY, in the C-terminal fragment of MMP-3/7-cleaved osteopontin as a novel ligand for α9β1 integrin is involved in the anti-type II collagen antibody-induced arthritis. PLoS ONE 9(12):e116210PubMedPubMedCentral

Kourepini E, Aggelakopoulou M, Alissafi T, Paschalidis N, Simoes DC, Panoutsakopoulou V (2014) Osteopontin expression by CD103- dendritic cells drives intestinal inflammation. Proc Natl Acad Sci USA 111(9):E856-865. https://doi.org/10.1073/pnas.1316447111PubMedPubMedCentralCrossRef

Kurzbach D, Platzer G, Schwarz TC, Henen MA, Konrat R, Hinderberger D (2013) Cooperative unfolding of compact conformations of the intrinsically disordered protein osteopontin. Biochemistry 52(31):5167–5175PubMed

Lampe MA, Patarca R, Iregui MV, Cantor H (1991) Polyclonal B cell activation by the Eta-1 cytokine and the development of systemic autoimmune disease. J Immunol 147(9):2902–2906PubMed

Leavenworth JW, Verbinnen B, Wang Q, Shen E, Cantor H (2015a) Intracellular osteopontin regulates homeostasis and function of natural killer cells. Proc Natl Acad Sci 112(2):494–499PubMed

Leavenworth JW, Verbinnen B, Yin J, Huang H, Cantor H (2015b) A p85α-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells. Nat Immunol 16(1):96–106. https://doi.org/10.1038/ni.3050PubMedCrossRef

Liu Y, Qian K, Li C, Ma Y, Chen X (2018) Roles of microRNA-539 and osteopontin in rheumatoid arthritis. Exp Ther Med 15(3):2681–2687PubMed

Maghraby HM, Refaei KE, Hassan MA, Hassan AS, AbdElazeem A (2018) Role of osteopontin in systemic lupus erythematosus. Int Ann Med. https://doi.org/10.24087/IAM.2018.2.2.417

Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM (2000) Osteoprotegerin is an αvβ3-induced, NF-κB-dependent survival factor for endothelial cells. J Biol Chem 275(28):20959–20962PubMed

Marastoni D, Magliozzi R, Bolzan A, Pisani AI, Rossi S, Crescenzo F et al (2021) CSF levels of CXCL12 and osteopontin as early markers of primary progressive multiple sclerosis. Neurol - Neuroimmunol Neuroinflamm 8(6):e1083. https://doi.org/10.1212/nxi.0000000000001083PubMedPubMedCentralCrossRef

McClean P, Irwin N, Hunter K, Gault V, Flatt P (2008) (Pro3) GIP [mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy. Br J Pharmacol 155(5):690–701PubMedPubMedCentral

McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205–2219PubMed

Melanitou E (2020) Investigation of type 1 diabetes in NOD mice knockout for the osteopontin gene. Gene 753:144785PubMed

Miyazaki T, Ono M, Qu WM, Zhang MC, Mori S, Nakatsuru S et al (2005) Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice. Eur J Immunol 35(5):1510–1520. https://doi.org/10.1002/eji.200425672PubMedCrossRef

Morimoto J, Kon S, Matsui Y, Uede T (2010) Osteopontin, as a target molecule for the treatment of inflammatory diseases. Curr Drug Targets 11(4):494–505PubMed

Murugaiyan G, Mittal A, Weiner HL (2008) Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 181(11):7480–7488PubMed

Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M et al (2002) Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol 29(10):2061–2067PubMed

Olek MJ (2021) Multiple sclerosis. Ann Intern Med. https://doi.org/10.7326/AITC202106150PubMedCrossRef

Ophascharoensuk V, Giachelli CM, Gordon K, Hughes J, Pichler R, Brown P et al (1999) Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 56(2):571–580. https://doi.org/10.1046/j.1523-1755.1999.00580.xPubMedCrossRef

Pellegrini M, Belz G, Bouillet P, Strasser A (2003) Shutdown of an acute T cell immune response to viral infection is mediated by the proapoptotic Bcl-2 homology 3-only protein Bim. Proc Natl Acad Sci 100(24):14175–14180PubMedPubMedCentral

Pender M, Nguyen K, McCombe P, Kerr J (1991) Apoptosis in the nervous system in experimental allergic encephalomyelitis. J Neurol Sci 104(1):81–87PubMed

Petrow PK, Hummel KM, Schedel J, Franz JK, Klein CL, Müller-Ladner U et al (2000) Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum 43(7):1597–1605PubMed

Pisetsky DS, Lipsky PE (2020) New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol 16(10):565–579PubMedPubMedCentral

Radmanesh F, Mahmoudi M, Yazdanpanah E, Keyvani V, Kia N, Nikpoor AR et al (2020) The immunomodulatory effects of mesenchymal stromal cell-based therapy in human and animal models of systemic lupus erythematosus. IUBMB Life 72(11):2366–2381PubMed

Rajabinejad M, Ranjbar S, Afshar Hezarkhani L, Salari F, Gorgin Karaji A, Rezaiemanesh A (2020) Regulatory T cells for amyotrophic lateral sclerosis/motor neuron disease: a clinical and preclinical systematic review. J Cell Physiol 235(6):5030–5040PubMed

Renkl AC, Wussler J, Ahrens T, Thoma K, Kon S, Uede T et al (2005) Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 106(3):946–955PubMed

Rittling S, Singh R (2015) Osteopontin in immune-mediated diseases. J Dent Res 94(12):1638–1645PubMedPubMedCentral

Rullo OJ, Woo JM, Parsa MF, Hoftman AD, Maranian P, Elashoff DA et al (2013) Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus. Arthritis Res Ther 15(1):R18. https://doi.org/10.1186/ar4150PubMedPubMedCentralCrossRef

Sakata M, Tsuruha J-I, Masuko-Hongo K, Nakamura H, Matsui T, Sudo A et al (2001) Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 28(7):1492–1495PubMed

Samimi Z, Kardideh B, Zafari P, Bahrehmand F, Roghani SA, Taghadosi M (2019) The impaired gene expression of adenosine monophosphate-activated kinase (AMPK), a key metabolic enzyme in leukocytes of newly diagnosed rheumatoid arthritis patients. Mol Biol Rep 46(6):6353–6360PubMed

Schulz G, Renkl AC, Seier A, Liaw L, Weiss JM (2008) Regulated osteopontin expression by dendritic cells decisively affects their migratory capacity. J Invest Dermatol 128(10):2541PubMedPubMedCentral

Senger DR, Wirth DF, Hynes RO (1979) Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16(4):885–893PubMed

Shao L, Zhang B, Wang L, Wu L, Kan Q, Fan K (2017) MMP-9-cleaved osteopontin isoform mediates tumor immune escape by inducing expansion of myeloid-derived suppressor cells. Biochem Biophys Res Commun 493(4):1478–1484PubMed

Shimizu Y, Ota K, Ikeguchi R, Kubo S, Kabasawa C, Uchiyama S (2013) Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica. J Neuroimmunol 263(1–2):148–151. https://doi.org/10.1016/j.jneuroim.2013.07.005PubMedCrossRef

Shinohara ML, Lu L, Bu J, Werneck MB, Kobayashi KS, Glimcher LH, Cantor H (2006) Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol 7(5):498–506. https://doi.org/10.1038/ni1327PubMedPubMedCentralCrossRef

Singh M, Ananthula S, Milhorn DM, Krishnaswamy G, Singh K (2007) Osteopontin: a novel inflammatory mediator of cardiovascular disease. Front Biosci 12(1):214–221PubMed

Sodek J, Ganss B, McKee M (2000) Osteopontin. Crit Rev Oral Biol Med 11(3):279–303PubMed

Spinelli FR, Garufi C, Truglia S, Pacucci VA, Morello F, Miranda F et al (2019) The role of osteopontin as a candidate biomarker of renal involvement in systemic lupus erythematosus. Clin Exp Rheumatol 37(6):899–905PubMed

Steinman L (2009) A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 9(6):440–447PubMed

Takanashi M, Oikawa K, Sudo K, Tanaka M, Fujita K, Ishikawa A et al (2009) Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse. Gene Ther 16(8):982–989PubMed

Take Y, Nakata K, Hashimoto J, Tsuboi H, Nishimoto N, Ochi T, Yoshikawa H (2009) Specifically modified osteopontin in rheumatoid arthritis fibroblast-like synoviocytes supports interaction with B cells and enhances production of interleukin-6. Arthritis Rheum 60(12):3591–3601PubMed

Tang R, Yang G, Zhang S, Wu C, Chen M (2014) Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease. Inflamm Bowel Dis 20(11):1950–1961. https://doi.org/10.1097/mib.0000000000000192PubMedCrossRef

Trivedi T, Franek BS, Green SL, Kariuki SN, Kumabe M, Mikolaitis RA et al (2011) Osteopontin alleles are associated with clinical characteristics in systemic lupus erythematosus. J Biomed Biotechnol 2011:802581. https://doi.org/10.1155/2011/802581PubMedPubMedCentralCrossRef

Tsokos GC (2020) Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol 21(6):605–614PubMedPubMedCentral

Uede T (2011) Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases. Pathol Int 61(5):265–280PubMed

Vogt M, Floris S, Killestein J, Knol D, Smits M, Barkhof F et al (2004) Osteopontin levels and increased disease activity in relapsing–remitting multiple sclerosis patients. J Neuroimmunol 155(1–2):155–160PubMed

Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19(5–6):333–345PubMed

Weber GF (2018) The Phylogeny of osteopontin—analysis of the protein sequence. Int J Mol Sci 19(9):2557PubMedCentral

Weber GF, Cantor H (2001) Differential roles of osteopontin/Eta-1 in early and late lpr disease. Clin Exp Immunol 126(3):578–583. https://doi.org/10.1046/j.1365-2249.2001.01702.xPubMedPubMedCentralCrossRef

Weiss J, Renkl A, Maier C, Kimmig M, Liaw L, Ahrens T et al (2001) Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J Exp Med 194(9):1219–1230PubMedPubMedCentral

Wong CK, Lit LC, Tam LS, Li EK, Lam CW (2005) Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus. Rheumatology (oxford) 44(5):602–606. https://doi.org/10.1093/rheumatology/keh558CrossRef

Wüthrich RP, Fan X, Ritthaler T, Sibalic V, Yu DJ, Loffing J, Kaissling B (1998) Enhanced osteopontin expression and macrophage infiltration in MRL-Fas(lpr) mice with lupus nephritis. Autoimmunity 28(3):139–150. https://doi.org/10.3109/08916939808996282PubMedCrossRef

Xu G, Nie H, Li N, Zheng W, Zhang D, Feng G et al (2005) Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Investig 115(4):1060–1067PubMedPubMedCentral

Yamaguchi Y, Hanashima S, Yagi H, Takahashi Y, Sasakawa H, Kurimoto E et al (2010) NMR characterization of intramolecular interaction of osteopontin, an intrinsically disordered protein with cryptic integrin-binding motifs. Biochem Biophys Res Commun 393(3):487–491PubMed

Yamamoto N, Nakashima T, Torikai M, Naruse T, Morimoto J, Kon S et al (2007) Successful treatment of collagen-induced arthritis in non-human primates by chimeric anti-osteopontin antibody. Int Immunopharmacol 7(11):1460–1470PubMed

Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S et al (2002) Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci 99(7):4556–4561PubMedPubMedCentral

Zhang F, Luo W, Li Y, Gao S, Lei G (2015a) Role of osteopontin in rheumatoid arthritis. Rheumatol Int 35(4):589–595PubMed

Zhang Y-M, Li M-X, Tang Z, Wang C-H (2015b) Wogonin suppresses osteopontin expression in adipocytes by activating PPARα. Acta Pharmacol Sin 36(8):987–997. https://doi.org/10.1038/aps.2015.37PubMedPubMedCentralCrossRef

Zhao K, Zhang M, Zhang L, Wang P, Song G, Liu B et al (2016) Intracellular osteopontin stabilizes TRAF3 to positively regulate innate antiviral response. Sci Rep 6(1):1–13

Zhao J, Jing J, Zhao W, Li X, Hou L, Zheng C et al (2020) Osteopontin exacerbates the progression of experimental autoimmune myasthenia gravis by affecting the differentiation of T cell subsets. Int Immunopharmacol 82:106335PubMed

Titel: Osteopontin in autoimmune disorders: current knowledge and future perspective
verfasst von: Canhua Xu
Yaohong Wu
Ning Liu
Publikationsdatum: 02.03.2022
Verlag: Springer International Publishing
Erschienen in: Inflammopharmacology / Ausgabe 2/2022
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-022-00932-0

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Osteopontin in autoimmune disorders: current knowledge and future perspective

Abstract

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Oral administration of essential oil from Psidium glaziovianum Kiaersk leaves alleviates pain and inflammation in mice

Comparative assessment of organic and inorganic tea leaf extract feeding on anxiety behaviour status of colchicine-induced rat model of Alzheimer’s disease

Effect of statins on the plasma/serum levels of inflammatory markers in patients with cardiovascular disease; a systematic review and meta-analysis of randomized clinical trials

Modulation of KIF17/NR2B crosstalk by tozasertib attenuates inflammatory pain in rats

Caralluma tuberculata exhibits analgesic and anti-arthritic potential by downregulating pro-inflammatory cytokines and attenuating oxidative stress

Correction to: Methanolic extracts of a selected Egyptian Vicia faba cultivar mitigate the oxidative/inflammatory burden and afford neuroprotection in a mouse model of Parkinson's disease